No

α-Amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) and α-aminomuconate-ε-semialdehyde dehydrogenase (AMSDH) are two neighboring enzymes in the L-tryptophan and 2-nitrobenzoic acid degradation pathways. The substrates of the two enzymes, α-amino-β-carboxymuconate-ε-semialdehyde (ACMS) and α-aminomuconate-ε-semialdehyde (2-AMS), are unstable and spontaneously decay to quinolinic acid and picolinic acid, respectively. ACMSD utilizes a divalent zinc metal as cofactor and is a member of the amidohydrolase superfamily. In this dissertation work, we have identified an important histidine residue in the active site that plays dual roles in tuning metal selectivity and activating a metal bound water ligand using mutagenesis, resonance Raman, EPR, crystallography, and ICP metal analysis techniques. The crystal structures of ACMSD from Pseudomonas fluorescens (PfACMSD) have been solved as homodimers in our laboratory while human ACMSD (hACMSD) was annotated as a monomer by another group. To resolve this structural difference, we used two conserved active site arginine residues as probes to study the oligomeriztion state of ACMSD and demonstrated that these two arginine residues are involved in substrate binding and that both Pf- and h- ACMSD are catalytically active only in the dimeric state. Subsequently, we solved the crystal structure of hACMSD and found it to be a homodimer in both catalytically active and inhibitor-bound forms. AMSDH is an NAD+ dependent enzyme and belongs to the aldehyde dehydrogenase superfamily. Due to the high instability of its substrate, AMSDH has not been studied at the molecular level prior to our work. We have cloned and expressed PfAMSDH in E. coli. The purified protein has high activity towards both 2-AMS and 2-hydroxymuconate semialdehyde (2-HMS), a stable substrate analog. We have successfully crystallized AMSDH with/without NAD+ and solved the crystal structure at up to 1.95 Å resolution. Substrate bound ternary complex structures were obtained by soaking the NAD+ containing crystals with 2-AMS or 2-HMS. Notably, two covalently bound catalytic intermediates were captured and characterized using a combination of crystallography, stopped-flow, single crystal spectroscopy, and mass spectrometry. The first catalytic working model of AMSDH has been proposed based on our success in structural and spectroscopic characterization of the enzyme in five catalytically relevant states in this dissertation work.

Conselho Nacional de Desenvolvimento Cientifico e Tecnológico / Fundação Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro / Neste trabalho foram sintetizados os heterociclos 3-carbetoxi-4(1H)-quinolona 98a-98o contendo substituintes flúor, cloro, bromo, iodo, metil, metoxi e nitro nas posições 6 ou 7, em rendimentos de 72 a 87%. Estes foram sililados com N,O-bis(trimetilsilil)trifluoracetamida (BSTFA) sendo posteriormente submetidos à reação de acoplamento com 1-O-acetil-2,3,5-tri-O-benzoil-β-D-ribofuranose (49), sob catálise do ácido de Lewis trimetilsililtrifluormetanossulfonato (TMSO-Tf), obtendo-se os respectivos ribonucleosídeos 3-carbetoxi-1-(2,3,5-tri-O-benzoil-β-D-ribofuranosil)-4(1H)-quinolonas 99a-99o em rendimentos 65 a 89%. A reação de O-desbenzoilação dos nucleosídeos 99, utilizando-se solução metanólica de carbonato de sódio levou aos ribonucleosídeos inéditos 3-carbometoxi-1-β-D-ribofuranosil-4(1H)-quinolona correspondentes (100) em rendimentos de 70 a 77%. Os ribonucleosídeos quinolônicos 100 (6-F, Cl, Br, Me e 7-F) foram utilizados como precursores na obtenção de derivados nucleosídicos bromo-O-acetilados do tipo 90. Nestas reações os produtos resultantes da bromoacetilação de 100 (6-Cl, Br, Me) foram obtidos como mistura de regioisômeros 2(3)-Br, 3(2)-acetato, na proporção de (3:1), (5:1) e (3:1), respectivamente. As reações com os nucleosideos 100 (6-F e 7-F) levaram `a formação dos derivados 2,3,5-tri-O-acetilados. Contudo, a reação de bromoacetilação do ácido 6-metil-1-β-D-ribofuranosil-4(1H)-quinolona-3-carboxílico levou ao bromoacetato 90e como único produto, em rendimento de 65%. Estes derivados bromo-O-acetilados foram submetidos a reação de β-eliminação redutiva promovida por metais empregando-se duas metodologias. A primeira utilizando-se liga de zinco-cobre em DMF como solvente, e a segunda usando-se lítio metálico em THF sob ultra-som, porém estas reações não produziram os produtos olefínicos desejados. Contudo, a β-eliminação redutiva de 90e empregando-se liga de zinco-cobre sob ultra-som, levou ao 2`,3`-didesidrodidesoxinucleosídeo esperado. A reação de desproteção regiosseletiva de nucleosídeos 2,3,5-tri-O-benzoilados (99), empregando-se metóxido de sódio em THF, levou aos ribonucleosídeos inéditos 5-O-benzoilados 103a-103c, em bons rendimentos. Estes compostos foram utilizados em tentativas de obtenção de derivados 2,3-tiocarbonatos cíclicos e 2,3-bisxantatos, sem que tenham sido obtidos os produtos esperados. Na pesquisa em busca de novos heterociclos pirimidoquinolínicos, com potencial atividade antiviral, as quinolonas 98 foram reagidas com uréia ou tiouréia em solução etanólica de hidróxido de sódio. Porém, as condições reacionais empregadas não foram satisfatórias, ocorrendo apenas a hidrólise do grupamento éster da posicao C3 do anel quinolonico. O mesmo procedimento foi aplicado aos nucleosídeos quinolônicos 99, obtendo-se neste caso os ribonucleosídeos 100 nos quais todos os grupos éster dos nucleosídeos originais foram hidrolisados, em rendimentos de 59 a 76%, o que nos levou a estabelecer metodologia adequada de obtenção de nucleosideos ácidos do tipo 100. Estes nucleosídeos foram submetidos a teste de atividade biológica frente ao vírus HSV-1 obtendo-se, obtendo-se bons resultados de inibição viral a uma concentração de 50 M, destacando-se os nucleosídeos contendo substituintes cloro e metil na posição 6 do anel quinolônico, que apresentaram um percentual de inibição igual a 99%. Paralelamente, foram realizadas as reações de N-alquilação dos heterociclos quinolônicos 98 levando às quinolonas N-etiladas 108 em rendimentos de 74 a 84%. Posteriormente, estas foram submetidas a reação de hidrólise básica obtendo-se os ácidos carboxílicos N-etilados do tipo 109 em rendimentos de 62 a 80%. A quinolona 108f (6-OMe) foi submetida a reação com tiouréia na presença de carbonato de potássio levando à obtenção do heterociclo inétido 6-etil-9-metoxi-4-oxo-2-tiono-2,3,4,6-tetraidropirimido[5,4-c]quinolina 94 em 72% de rendimento. Para obtenção de novos heterociclos quinolônicos contendo substituintes triazólicos, foram sintetizados as aminoquinolonas 108o e 108p em rendimentos de 70 e 72%, respectivamente, por redução das nitroquinolonas 108g e 108n. Inicialmente, estas foram submetidas a reação de conversão na enamina desejada, que produziria posteriormente o núcleo triazólico. Entretanto, não se obteve em ambos os casos as enaminas em questão. Assim, foi sintetizado o aminoacrilato 104p, em 75% de rendimento, o qual foi entao reagido com diazomalonaldeído, levando à formação do núcleo triazólico, tendo no entanto ocorrido subsequente reação de condensação entre o grupo aldeídico do anel triazólico e o grupo amino do aminoacrilato 104p, obtendo-se como produto final a imina 119 em 75% de rendimento. Esta imina foi então submetida a reação de hidrólise ácida, obtendo-se o acrilato triazólico 118 em 65% de rendimento. / In the present work the 6 and 7 substituted 3-carboethoxy-4(1H)-quinolones 98a-98o (fluorine, chlorine, bromine, iodine, methyl, methoxy and nitro) were synthesized in 72-87% yields. These quinolones were silylated by using bis-(trimethyl)trifluoroacetamide (BSTFA). Glycosylation of these silylated heterocycles was accomplished by their treatment with 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (49) in the presence of Trimethylsilyltrifluoromethanesulphonate ( TMSO-Tf), providing the desired ribonucleosides 3-carboethoxy-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)- 4(1H)-quinolones 99a-99o, in 65-89% yields. The de-O-benzoylation reaction of 99, using methanolic sodium carbonate solution led to the new 3-carbomethoxy-1- β-D-ribofuranosyl)- 4(1H)-quinolones 100 in 70-77% yields. The 6-F,Cl, Br, Me and 7-F-ribonucleosides 100 were used as precursors in the synthesis of their respective bromoacethylated derivatives 90. In these reactions, the bromoacetylation of 100 (6-Cl, Br and Me) yielded the corresponding mixture of regioisomeric bromoacetates 3(2)-Br, 2(3)-O-acetyl, being 2-O-acetyl-3-Br derivative the majoritary one ( 3:1, 5:1 and 3:1, respectively). This reaction when applied to 6-fluoro and 7-fluoro ribonucleosides 100a and 100f afforded the corresponding 2,3,5-tri-O-acetylated derivatives. However, the same reaction when using 6-methyl-1-β-D-ribofuranosyl-4(1H)-quinolone-3-carboxylic acid (100m) as the starting material produced the new 6-methyl-1-(2,5-di-O-acetyl-3-bromo-3-deoxy-β-D-ribofuranosyl-4(1H)quinolone-3-carboxylic acid (90e) as the only regioisomer in 65% yield. The β-Elimination reactions with these bromo-O-acetylated nucleosides were attempted by two methodologies. The first one using zinc-copper alloy in DMF and the second one using lithium in THF under ultrasound. These reactions failed to give the olefinec products. However, when the pure bromoacetate 90e was reacted with zinc-copper alloy, in DMF, under ultrasound, the desired 2`.3`-didesydrodidesoxy ribonucleoside was obtained. Regioselective deprotection of 2,3,5-tri-O-benzoylated nucleosides 99 by using sodium methoxide in THF led to the new 5-O-benzoylated ribonucleosides 103a-103c in good yields. These substances were employed in attempts to obtain 2,3-cyclic thiocarbonates or to obtain 2,3-bisxanthates, unsuccessfuly. In the search for new heterocyclic nucleosides having pyrimidoquinoline ring, with potential antiviral activity, the quinolones 98 were reacted with urea or thiourea in sodium hydroxide solution leding only to the product in which the ester moiety of the starting material was hydrolyzed The same procedure was applied to the nucleosides 99 affording the ribonucleosides 100 in which all the ester groups of the protected ribonucleosides XV were hydrolyzed (59-76% yields). Additional efforts to obtain new pyrimidoquinoline derivatives were done. The quinolones 98 were alkylated with ethyl bromide in DMF producing the corresponding N-ethylquinolones 108 in 74-84% yields. Subsequently basic hydrolysis of the esther group at C3 led to carboxylic acids derivatives XXI in 62-80% yields. The condensation of 108f (R=6-OMe) with thiourea in the presence of sodium carbonate resulted in the isolation of the new heterocycle 6-ethyl-9-methoxy-4-oxo-2-thione-2,3,4,6-tetrahydropyrimido[5,4-c]quinoline (94), in 72% yield. In the search of new quinolonic derivatives containing the tryazolic nucleous as substituint the aminoquinolones 108o and 108p were synthesized in 70 and 72% yields respectively, by reduction of the nitroquinolones 108g and 108n. In the first approach the amines were reacted with 1,3-dicaronylcompounds aiming to obtain the corresponding enamino esters, which would produce the tryazolic ring. However, this reaction failed to give the desired product. In order to overcome this problem, the aminoacrylate 104p was synthesized (75% yield), and subsequently reacted with diazomalonaldehyde forming the tryazolic moiety, followed by a condensation reaction leading to the iminoderivative (119), in 75% yield, which was hydrolyzed, under acid conditions, giving the tryazolic acrylate 118, in 65% yield.

AIDS Dementia Complex (ADC) is a neurodegenerative disorder implicated in HIV-1 infection that is associated with elevated levels of the neurotoxin, quinolinic acid (QA) which causes a cascade of events to occur, leading to the production of reactive oxygen species (ROS), these being ultimately responsible for oxidative neurotoxicity. In clinical studies, Non-nucleoside reverse transcriptase inhibitors (NNRTIs), efavirenz (EFV) and nevirapine (NVP) have been shown to potentially delay the progressive degeneration of neurons, thus reducing the frequency and neurological deficits associated with ADC. Despite these neuroprotective implications, there is still no biochemical data to demonstrate the mechanisms through which these agents offer neuroprotection. The present study aims to elucidate and further characterize the possible antioxidant and neuroprotective mechanisms of NVP and EFV in vitro and in vivo, using QA-induced neurotoxicity as a model. Research has demonstrated that antioxidants and metal chelators have the ability to offer neuroprotection against free radical induced injury and may be beneficial in the prevention or treatment of neurodegeneration. Hence the antioxidant and metal binding properties of these agents were investigated respectively. Inorganic studies, including the 1, 1-diphenyl-2 picrylhydrazyl (DPPH) assay, show that these agents readily scavenge free radicals in vitro, thus postulating the antioxidant property of these agents. The enhancement of superoxide radical generation and iron mediated Fenton reaction by QA is related to lipid peroxidation in biological systems, the extent of which was assayed using the nitroblue tetrazolium and thiobarbituric acid method respectively. Both agents significantly curtail QA-induced lipid peroxidation and potentially scavenge superoxide anions generated by cyanide in vitro. Furthermore, in vivo results demonstrate the ability of NVP and EFV to protect hippocampal neurons against lipid peroxidation induced by QA and superoxide radicals generated as a consequence thereof. The alleviation of QA-induced oxidative stress in vitro possibly occurs through the binding of iron (II) and / or iron (III), and this argument is further strengthened by the ability of EFV and not NVP to reduce iron (II)-induced lipid peroxidation in vitro directly. In addition the ferrozine and electrochemistry assay were used to measure the extent of iron (II) Fe[superscript 2+] and iron (III) Fe[superscript 3+] chelation activity. Both assays demonstrate that these agents bind iron (II) and iron (III), and prevent redox recycling of iron and subsequent complexation of Fe[superscript 2+] with QA which enhances neuronal damage. Both NNRTIs inhibit the endogenous biosynthesis of QA by inhibiting liver tryptophan 2, 3-dioxygenase activity in vivo and subsequently increasing hippocampal serotonin levels. Furthermore, these agents reduce the turnover of hippocampal serotonin to 5-hydroxyindole acetic acid. NVP and not EFV increase 5-hydroxyindole acetic acid and norepinephrine levels in the hippocampus. The results of the pineal indole metabolism study show that NVP increases the synthesis of melatonin, but decreases N-acetylserotonin, 5-hydroxyindole acetic acid and 5-hydroxytryptophol levels. Furthermore, it shows that EFV decreases 5-hydroxyindole acetic acid and melatonin synthesis. Behavioural studies using a Morris water maze show that the post-treatment of rats with NVP and EFV significantly improves QA-induced spatial memory deficits in the hippocampus. This study therefore provides novel information regarding the neuroprotective mechanisms of NVP and EFV. These findings strengthen the argument that these NNRTIs not only have antiviral effects but possess potential neuroprotective properties, which may contribute to the effectiveness of these drugs in the treatment of ADC.

Tryptophan is metabolised along the kynurenine pathway under the influence of tryptophan 2,3 dioxygenase and indoleamine 2,3 dioxygenase. Quinolinic acid and kynurenine, two neuroactive metabolites of the kynurenine pathway are, in chronic renal failure patients, considered as uraemic toxins. Related research is generally hampered by the non-availability of relevant analytical techniques. The primary aim of this study was, therefore, to develop and validate suitable methods for the determination of tryptophan, kynurenine and quinolinic acid. The second aim was to quantify the levels of these substances in the blood of chronic renal failure patients on renal replacement therapies and to compare the levels of haemodialysis patients to those on peritoneal dialysis. Patients’ quality of life was investigated relative to disturbances in tryptophan metabolism. Gas chromatography coupled to mass spectrometry (GC-MS) gave the best results for the analysis of tryptophan, kynurenine and quinolinic acid. A Hewlett Packard HP GC 6890 series gas chromatographer was coupled to a MS 5973 series mass spectrometer. Analytes were separated on a DB-5MS column with a nominal length of 30 metres, a diameter of 250.0 µm and film thickness of 0.10 µm. Helium was used as carrier gas, and the chromatographic analysis run time 12.5 minutes. The validation results were within the acceptance criteria for newly developed methods. The linear calibration curves constructed for all of the analytes gave r2 correlation coefficients >0.99. Other validation data such as precision, bias, accuracy and stability all fell within acceptable validation limits. In the study on chronic renal failure patients significant differences were seen between patients and controls. Tryptophan levels were 5.34 SD 5.04 µM for the haemodialysis group, 6.73 SD 3.18 µM for the peritoneal dialysis group and 28.4 SD 4.31 µM for the control group. Kynurenine levels were 4.7 SD 1.9 µM for the haemodialysis group, 2.9 SD 2.0 µM for the peritoneal dialysis group and 2.1 SD 0.6 µM for the control group. Quinolinic acid levels were 4.9 SD 2.0 µM for the haemodialysis group, 2.8 SD 2.0 µM for the peritoneal dialysis group and 0.3 SD 0.1 µM for the control group. Tryptophan was lower for the total patient group than for controls with significantly lower levels for haemodialysis versus control (p<0.05) and peritoneal dialysis versus control (p<0.05). Kynurenine levels were higher in the total patient group with significantly higher levels for the haemodialysis versus control group (p=0.0001). The patient groups had higher quinolinic acid levels with significantly higher levels for the haemodialysis versus control (p<0.05) and peritoneal dialysis versus control (p<0.05) groups. This study was the first to determine the three substances simultaneously in both haemodialysis and peritoneal dialysis patients. The study showed significant tryptophan depletion, as well as kynurenine and quinolinic acid accumulation for both groups. No significant differences were found between the patient groups other than higher kynurenine levels in the haemodialysis group. The quality of life (SF-36) was largely similar in the two patient groups. This decrease in the quality of life strongly correlated with the degree of tryptophan depletion. / Dissertation (MSc)--University of Pretoria, 2008. / Chemical Pathology / unrestricted

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Excessive formation of reactive oxygen species (ROS) and disruption of glutamate uptake have been hypothesized as key mechanisms contributing to quinolinic acid (QA)- induced toxicity. Thus, here we investigate if the use of diphenyl diselenide (PhSe)2, guanosine (GUO) and MK-801, alone or in combination, could protect rat brain slices from QA-induced toxicity. QA (1 mM) increased ROS formation, thiobarbituric acid reactive substances (TBARS) and decreased cell viability after 2 h of exposure. (PhSe)2 (1 μM) protected against this ROS formation in the cortex and the striatum and also prevented decreases in cell viability induced by QA. (PhSe)2 (5 μM) prevented ROS formation in the hippocampus. GUO (10 and 100 μM) blocked the increase in ROS formation caused by QA and MK-801 (20 and 100 μM) abolished the pro-oxidant effect of QA. When the non effective concentrations were used in combination produced a decrease in ROS formation, mainly (PhSe)2 + GUO and (PhSe)2 + GUO + MK-801. These results demonstrate that this combination could be effective to avoid toxic effects caused by high concentrations of QA. Furthermore, the data obtained in the ROS formation and cellular viability assays suggest different pathways in amelioration of QA toxicity present in the neurodegenerative process. / A formação excessiva de espécies reativas de oxigênio (ROS) e alterações na captação de glutamato têm sido associadas como mecanismos chave que contribuem para toxicidade induzida pelo ácido quinolínico (AQ). Assim, nós investigamos se a utilização do disseleneto de difenila (PhSe)2, guanosina (GUO) e MK-801, isoladamente ou em combinação, podem proteger as fatias de regiões cerebrais de ratos da toxicidade induzida por AQ. AQ (1 mM) aumentou a formação de ROS, substâncias reativas ao ácido tiobarbitúrico (TBARS) e diminuiu a viabilidade celular após 2h de exposição. (PhSe)2 (1 μM) protegeu contra esta formação de ROS no córtex e no estriado e além disso preveniu a diminuição da viabilidade celular induzida pelo AQ. (PhSe)2 (5 μM) preveniu a formação de ROS no hipocampo. GUO (10 e 100 μM) bloqueou o aumento na formação de ROS causada pelo AQ e MK-801 (20 e 100 μM) aboliu o efeito pró-oxidante do AQ. Quando as concentrações não-efetivas foram usadas em combinação produziram uma diminuição na formação de ROS, principalmente (PhSe)2 + GUO e (PhSe)2 + GUO + MK-801. Estes resultados demonstram que esta combinação pode ser eficaz para evitar os efeitos tóxicos provocados por concentrações elevadas do AQ. Além disso, os dados obtidos nos ensaios de formação de ROS e viabilidade celular sugerem diferentes vias de atuação na melhora da toxicidade induzida pelo AQ presente no processo neurodegenerativo.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Recent data from the literature have suggested that some Krebs cycle intermediates could act as potent antioxidant agents, both in vitro and in vivo, against a variety of pro-oxidant agents. However, the mechanism(s) involved in the antioxidant effect of Krebs cycle intermediates are not fully understood. Additionally, there are scarce data in the literature taking into account the in vitro effect of Krebs cycle intermediates during oxidative stress conditions. Thus, the aim of this study was to determine the effect of some Krebs cycle intermediates on lipid peroxidation induced in vitro by different pro-oxidant agents, and the mechanism(s) by which they act. Firstly, we investigated the effect and the mechanism(s) by which malonate and quinolinic acid modulate the thiobarbituric acid- reactive species (TBARS) production in vitro, using rat brain S1 preparations (Article 1). The present results showed that the malonate-induced TBARS production was not changed by potassium cyanide or MK-801. However, the pro-oxidant effect of quinolinic acid was significantly prevented by MK-801. In addition we found that malonate was able to form complexes with iron ions (Fe2+), but these complexes were not able to interfere with in vitro deoxyribose degradation assays. Based on the results presented, we conclude that malonate pro-oxidant activity in vitro seems to be independent of the NMDA receptors activity. Additionally, we suggest that the malonate effect, in these conditions, is due to its ability to form complexes with iron ions, thus modulating an adequate ratio Fe2+/Fe3+ that could cause an increase in free radicals generation. In contrast, the quinolinic acid effect seems to be dependent of the NMDA receptors activation. However, we can not rule out the involvement of iron ions in quinolinic acid toxicity under our assay conditions. An other objective of this study was to investigate the effect of some Krebs cycle intermediates on quinolinic acid- or iron (Fe2+)-induced TBARS production in the rat brain S1 preparations, and the mechanism(s) by which they act (Article 2). The results showed that oxaloacetate, citrate, succinate, and malate were able to significantly prevent both basal and quinolinic acid- or iron-induced TBARS production. However, α-ketoglutarate induced per se a significant increase in basal TBARS production. The addition of potassium cyanide or the heat-treatment of S1 at 100ºC during 10 min completely abolished the antioxidant succinate activity, without change the effect of other Krebs cycle intermediates studied. Except for succinate, all intermediates used in this study were able to form complexes with iron (Fe2+) ions, however only oxaloacetate and α-ketoglutarate significantly prevented deoxyribose degradation induced by hydrogen peroxide. Based on the results presented, we concluded that oxaloacetate, malate, succinate, and citrate could act as antioxidants under basal, and under quinolinic acid- or iron- induced TBARS production, whereas α-ketoglutarate act as a pro-oxidant agent per se. The mechanism(s) by which citrate, malate, and oxaloacetate acts seems to be related to their ability to form complexes with iron (Fe2+) ions, thus modulating the iron redox cycle. In contrast, the succinate antioxidant effect seems to be dependent of the succinate dehydrogenase (SDH) activity. / Dados recentes na literatura têm relatado que alguns intermediários do ciclo de Krebs podem agir como potentes antioxidantes, tanto in vitro, quanto in vivo, em diversos sistemas pró-oxidantes. Porém, o(s) mecanismo(s) através dos qual(is) os intermediários do ciclo de Krebs exercem suas atividades antioxidantes não são completamente entendidas. Considerando a escassez de dados in vitro na literatura a respeito do efeito desses intermediários durante situações de estresse oxidativo, o presente trabalho tem como objetivo determinar o efeito de intermediários do ciclo de Krebs sob a peroxidação lipídica induzida por diferentes agentes pró-oxidantes in vitro, bem como investigar o(s) mecanismo(s) de ação dos mesmos. Primeiramente investigamos o efeito e o(s) mecanismo(s) pelo(s) qual(is) o malonato e o ácido quinolínico modulam a produção de espécies reativas ao ácido tiobarbitúrico (TBARS) em S1 de cérebro de ratos, in vitro (artigo 1). Os resultados obtidos mostraram um aumento na produção de TBARS induzido pelo malonato, o qual não foi modificado pela adição de cianeto de potássio, nem pelo MK-801. Por outro lado, o efeito pró-oxidante do ácido quinolínico foi significativamente prevenido pelo MK-801. Observamos ainda que o malonato foi capaz de formar complexos com íons ferrosos e que esses complexos não foram capazes de interferir nos ensaios da degradação da desoxirribose in vitro. Portanto, com base nos resultados encontrados, concluímos que o efeito pró-oxidante do malonato in vitro parece ser independente da atividade dos receptores NMDA. Os resultados sugerem que o efeito do malonato nessas condições deve-se principalmente a sua capacidade de interagir com íons ferro, modulando uma razão Fe2+/Fe3+ que favorece a geração de radicais livres. Por outro lado, o efeito do ácido quinolínico parece ser devido à ativação dos receptores NMDA. Porém, não podemos excluir a participação dos íons ferro para a toxicidade do mesmo nessas condições. Outro foco deste estudo foi investigar o efeito de alguns intermediários do ciclo de Krebs na produção de TBARS induzida por ácido quinolínico ou ferro em S1 de cérebro de ratos in vitro, bem como investigar o(s) mecanismo(s) de ação dos mesmos (artigo 2). Os resultados mostraram que o oxaloacetato, o citrato, o sucinato e o malato foram capazes de reduzir significativamente a produção de TBARS basal, bem como a induzida por ácido quinolínico ou ferro. Por outro lado, o α-cetoglutarato foi capaz de induzir per se um significativo aumento na produção de TBARS. A adição de cianeto de potássio, bem como o pré-tratamento do S1 por 10 min a 100ºC aboliram completamente o efeito antioxidante do sucinato, sem interferir significativamente no efeito dos demais intermediários estudados. Todos os intermediários estudados, exceto o sucinato, foram capazes de quelar íons ferro, porém somente o oxaloacetato e o α-cetoglutarato foram capazes de prevenir a degradação da desoxirribose induzida por peróxido de hidrogênio. Com base nos resultados obtidos, podemos concluir que o oxaloacetato, o malato o sucinato e o citrato agem como antioxidantes sob condições basais ou em presença do ácido quinolínico ou ferro, enquanto que o α-cetoglutarato age como um agente pró-oxidante per se. O mecanismo pelo qual o citrato, o malato e o oxaloacetato exercem seus efeitos antioxidantes parece ser devido à capacidade desses em interagir com íons ferro modulando o ciclo redox desse. Por outro lado, o efeito do sucinato parece ser devido à atividade da enzima succinato desidrogenase (SDH).

Spermine (SPM) is an aliphatic amine which contains four nucleophilic centers and is found in all eukaryotic cells, including nervous cells. It belongs to the group of polyamines, which are molecules associated with both neuroprotection and neurotoxicity. The aim of this study was to investigate the effects of spermine on some parameters of toxicity induced by striatal administration of quinolinic acid (QA), an experimental model of Huntington s disease in adult and male Wistar rats. The intrastriatal administration of QA (180 nmol/site) induced contralateral rotations and increase the number of contralateral body swings. The previous striatal administration of SPM caused mixed effects: at the dose of 0.1 nmol/site increased the number of contralateral rotations; but at 10 nmol/site it reduced both the number of rotations and the contralateral body swings induced by QA. The mechanism by which SPM decreases these motor alterations is probably through its interaction with the NMDA receptor, since the co-administration with arcaine (antagonist of polyamine binding sites on this receptor) reversed its protective effect. The increase of protein carbonyl content induced by QA (180 nmol/site) in striatum of rats was prevented by the administration of 10 nmol/site of SPM. Besides, the bilateral striatal injection of QA (180 nmol/site) impaired the performance in the recognition memory task. The post-training striatal administration of SPM (0.1 and 1 nmol/site) reversed the QA-induced cognitive deficit. It was also evaluated whether spermine prevented QA-induced neuromorphological alterations. QA caused striatal neuronal degeneration and reactive astrogliosis. SPM, at the dose that improved the cognitive performance (0.1 nmol/site), had no effect on striatal neuronal degeneration but reversed the intense astrocytic reaction induced by QA. These results suggest that SPM has neuroprotective properties, presenting a dose dependent pattern of polyamine, in this experimental model of Huntington disease. / A espermina (SPM) é uma amina alifática, contendo quatro centros nucleofílicos e é encontrada em todas as células eucarióticas, incluindo células nervosas. Ela pertence ao grupo das poliaminas, moléculas responsáveis tanto por efeitos neuroprotetores quanto neurotóxicos. O objetivo do presente trabalho foi investigar os efeitos da SPM sobre alguns parâmetros de toxicidade induzidos pela administração estriatal de ácido quinolínico (AQ), um modelo experimental da doença de Huntington em ratos Wistar machos adultos. A administração intraestriatal unilateral de AQ (180 nmol/sítio) induziu o aparecimento de rotações contralaterais e aumento do percentual de balanços corporais contralaterais. A prévia administração estriatal de SPM mostrou efeitos diversos: na dose de 0,1 nmol/sítio aumentou o número de rotações; porém na dose de 10 nmol/sítio ela diminuiu tanto o número de rotações quanto o percentual de balanços corporais contralaterais induzidos pelo AQ. O mecanismo pelo qual a SPM diminui estas alterações motoras é, provavelmente, devido à sua interação com o receptor NMDA, uma vez que sua co-administração com a arcaína (antagonista do sítio das poliaminas neste receptor) reverteu o efeito protetor da mesma. A administração de 10 nmol/sítio de SPM preveniu o aumento do conteúdo de proteína carbonil induzida pela injeção de AQ (180 nmol/sítio) no estriado de ratos. Além disso, foi observado prejuízo cognitivo na tarefa de reconhecimento de objetos após a injeção estriatal bilateral de AQ (180 nmol/sítio). A administração estriatal póstreino de SPM (0,1 e 1 nmol/sítio) reverteu este déficit cognitivo induzido pelo AQ. Para avaliação das alterações neuromorfológicas neste modelo foram observadas degeneração neuronal e reação astrocitária. O AQ aumentou significativamente a degeneração de neurônios estriatais e a astrogliose reativa. A SPM, na menor dose que melhorou o desempenho cognitivo (0,1 nmol/sítio), não teve efeito sobre a degeneração neuronal estriatal; no entanto, ela foi capaz de reverter a intensa reação astrocitária induzida pela injeção de AQ. Estes resultados sugerem que a SPM tem propriedades neuroprotetoras, que apresentam um padrão dependente da dose da poliamina, neste modelo experimental da doença de Huntington.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Previous data from the literature have shown that some Krebs cycle intermediates could act as antioxidant in several models, both in vitro and in vivo. However, the mechanism(s) involved in the antioxidant effect of Krebs cycle intermediates are not fully understood. Additionally, there are scarce data in the literature taking into account the in vitro effect of Krebs cycle intermediates during oxidative stress conditions. Thus, the aim of this study was to determine the effect of some Krebs cycle intermediates on lipid peroxidation induced in vitro by different pro-oxidant agents, and the mechanism(s) by which they act. Furthermore, it was necessary elucidate the mechanisms by which the different pro-oxidants acts under in vitro conditions. The present results showed that the malonate-induced TBARS production was not changed by potassium cyanide or MK-801. However, the pro-oxidant effect of quinolinic acid was significantly prevented by MK-801. In addition we found that both malonate and oxalate were able to form complexes with iron ions (Fe2+). Based on the presented results, we conclude that malonate pro-oxidant activity in vitro seems to be independent of the secondary excitotoxicity via indirect NMDA receptors activation. Additionally, we suggest that both the malonate and oxalate effect, in these experimental conditions, is due to its ability to form complexes with iron ions, thus modulating an adequate ratio Fe2+/Fe3+ that could cause an increase in free radicals generation. In contrast, the quinolinic acid effect seems to be dependent of the NMDA receptors activation. However, we can not rule out the involvement of iron ions in quinolinic acid toxicity under our assay conditions. Another objective of this study was to investigate the effect of some Krebs cycle intermediates against either basal or induced TBARS production, using rat brain S1 preparations and the mechanism(s) by which they act. The results showed that oxaloacetate, citrate, succinate, and malate were able to significantly prevent both basal and quinolinic acid-, iron- or malonate-induced TBARS production. On the other hand, fumarate prevented only malonate-induced TBARS production, without effect under basal conditions. However, α-ketoglutarate induced per se a significant increase in basal TBARS production. The antioxidant activity of fumarate and succinate were completely abolished when S1 was submitted to heat-treatment at 100ºC during 10 min. Likewise, potassium cyanide completely abolished the antioxidant effect of succinate. The effect of other Krebs cycle intermediates studied was unchanged with respect to heat-treatment, or cyanide. Except for succinate and fumarate, all intermediates used in this study were able to form complexes with iron (Fe2+) ions, however only oxaloacetate and α-ketoglutarate significantly prevented deoxyribose degradation induced by hydrogen peroxide. Based on the results presented, we concluded that oxaloacetate, malate, succinate, fumarate and citrate could act as antioxidants under such conditions, whereas α-ketoglutarate acts as a pro-oxidant agent per se. The mechanism(s) by which citrate, malate, and oxaloacetate acts seems to be related to their ability to form complexes with iron (Fe2+) ions, thus modulating the iron redox cycle. In contrast, the succinate and fumarate antioxidant effect seems to be dependent of the some enzymatic system. / Dados prévios da literatura têm mostrado que alguns intermediários do ciclo de Krebs podem agir como antioxidantes em diversos modelos, tanto in vitro, quanto in vivo. Porém, o(s) mecanismo(s) através dos qual(is) esses intermediários exercem suas atividades antioxidantes não são completamente entendidas. Considerando a escassez de dados na literatura a respeito do efeito dos intermediários do ciclo de Krebs durante situações de estresse oxidativo, o presente trabalho teve por objetivo determinar o efeito desses sob a peroxidação lipídica induzida por diferentes agentes pró-oxidantes in vitro, bem como investigar o(s) mecanismo(s) de ação dos mesmos. Além disso, faz-se necessário caracterizar o(s) mecanismos(s) pelo(s) qual(is) os diferentes pró-oxidantes agem nos sistemas in vitro. Os resultados dessa tese mostraram que a atividade pró-oxidante in vitro do malonato não foi modificada pela adição de cianeto de potássio, nem pelo MK-801. Por outro lado, o efeito pró-oxidante do ácido quinolínico foi significativamente prevenido pelo MK-801. Observamos ainda que o malonato, e também o oxalato foram capazes de formar complexos com íons ferrosos. Portanto, com base nos resultados encontrados, concluímos que o efeito pró-oxidante do malonato in vitro parece ser independente da excitotoxicidade secundária, conseqüência da ativação indireta dos receptores NMDA. Os resultados sugerem que o efeito do malonato e do oxalato nessas condições experimentais deve-se principalmente a sua capacidade de interagir com íons ferro, modulando uma razão Fe2+/Fe3+ que favorece a geração de radicais livres. Por outro lado, o efeito do ácido quinolínico parece ser devido à ativação dos receptores NMDA. Porém, não podemos excluir a participação dos íons ferro para a toxicidade do mesmo nessas condições. Outro foco deste estudo foi investigar o efeito de alguns intermediários do ciclo de Krebs na produção de TBARS basal ou induzida por diferentes pró-oxidantes em S1 de cérebro de ratos in vitro, bem como investigar o(s) mecanismo(s) de ação dos mesmos. Os resultados mostraram que o oxaloacetato, o citrato, o sucinato e o malato foram capazes de reduzir significativamente a produção de TBARS basal, bem como a induzida por ácido quinolínico, ferro ou malonato. O fumarato, por sua vez, teve efeito antioxidante somente sobre a produção de TBARS induzida. Por outro lado, o α-cetoglutarato foi capaz de induzir per se um significativo aumento na produção de TBARS. O efeito antioxidante do fumarato e do sucinato foi completamente abolido quando o S1 foi submetido a um prétratamento por 10 min a 100ºC, enquanto que o efeito dos demais intermediários permaneceu inalterado. Da mesma forma, a adição de cianeto de potássio aboliu completamente o efeito antioxidante do sucinato sem interferir significativamente no efeito dos demais intermediários estudados. Todos os intermediários estudados, exceto o sucinato e o fumarato, foram capazes de quelar íons ferro, porém somente o oxaloacetato e o α- cetoglutarato foram capazes de prevenir a degradação da desoxirribose induzida por peróxido de hidrogênio. Com base nos resultados obtidos, podemos concluir que o oxaloacetato, o malato, o sucinato, o fumarato e o citrato agem como antioxidantes sob determinadas condições, enquanto que o α-cetoglutarato age como um agente pró-oxidante per se. O mecanismo pelo qual o citrato, o malato e o oxaloacetato exercem seus efeitos antioxidantes parece ser devido à capacidade desses em interagir com íons ferro modulando o ciclo redox desse. Por outro lado, o efeito do sucinato e do fumarato parece ser devido a alguma atividade enzimática.

The purpose of this thesis was to develop methodology by which treatments for the cognitive impairments in Huntington's disease (HD) could be tested. As such, the thesis focused mainly on evaluating rats with quinolinic acid (QA) lesions of the striatum, as this manipulation mimics some aspects of the neural damage in Huntington's disease, to try to identify cognitive deficits of HD resulting from cell loss in the striatum. In the first part (Chapters 3-5), the role of the striatum in implicit memory was investigated. Chapter 3 compared the performance of rats and humans on a reaction time task that evaluated implicit memory by presenting visual stimuli with differing probabilities which change over time. Although rats made higher percentage of incorrect responses and late errors, both groups showed a similar pattern of reaction times. Chapter 4 investigated whether implicit memory (the computation of probabilities to predict the location of a stimulus) was affected by selective blockade of dopaminergic transmission at the D1 or D2 receptors by SCH-23390 and raclopride, respectively. Reaction times were slower with SCH-23390 and raclopride, but only SCH-23390 reduced errors to the least probable target location. Chapter 5 used the same task to evaluate implicit memory in rats with QA lesions of the dorsomedial striatum (DMS). Implicit memory was not affected by lesions of the DMS, which suggested that once a task that requires implicit memory has been learned, the DMS was not involved in sustaining the performance of the task. The second part of this thesis (Chapter 6), explored the contribution of the DMS in habit formation. DMS lesioned rats did not show habitual responding, and were not impaired in learning a new goal-directed behaviour. The third part (Chapters 7 and 8), investigated the role of the dorsal striatum in reversal learning, attentional set-formation, and set-shifting. Dorsal striatum lesioned rats were not impaired in reversal learning, but had a diminished shift-cost, which suggested that dorsal striatum lesions disrupted the formation of attentional sets. These results showed that although QA lesions of the dorsal striatum mimic some aspects of the neural damage in HD, they did not result in the same cognitive deficits observed in patients with HD, at least using the tasks presented in this thesis. However, other animal models of HD could be evaluated using the different tasks presented in this thesis to continue the search of a reliable animal model of HD in which treatments for the disease could be evaluated.